















































Knowledge and application of European
Society of Cardiology (ESC) Guidelines in
themanagement of mitral regurgitation:
this is not bad but we can domuch better
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This editorial refers to ‘Educational needs and application
of guidelines in the management of patients with mitral re-
gurgitation. A European mixed-methods study’†, by B. Iung
et al., on page 1295.
Mitral regurgitation (MR) is one of the most challenging valvular heart
diseases (VHDs) to diagnose and manage. It is thus extremely import-
ant and useful for the medical community to have high-quality and
well-disseminated guidelines.1,2 However, this exercise may become
futile if we do not know whether the physicians are aware of these
guidelines and apply them in real-life clinical practice. In this issue of
the journal, Iung et al. reported the results of an elegant study in
which they performed a mixed-methods educational needs assess-
ment.3 An online survey was undertaken using three case scenarios
(asymptomatic severe primary MR, symptomatic severe primary MR
in the elderly, and severe secondary MR) with 115 primary care phys-
icians (PCPs) and 439 cardiologists or cardiac surgeons from seven
European countries. The important good news of this survey was
that ESC guidelines are widely used by European cardiologists.
However, it also revealed some bad news and need for
improvement.
Underuse of systematic
auscultation by the PCPs
Although systematic auscultation is probably the best way to screen
for VHD, it was performed by only 54% of PCPs in asymptomatic pa-
tients. The decline in the utilization and training of cardiac ausculta-
tion is an unfortunate but most probably irreversible trend. Within
the past four decades, the role of the stethoscope has indeed evolved
from the primary screening and diagnostic tool in medicine to more
an ostentatious sign of the healthcare professional. Not only is the
stethoscope used less and less by PCPs and cardiologists, but their
ability to detect and interpret heart sounds adequately has also deter-
iorated over time. This loss of expertise in cardiac auscultation is of
particular concern for the PCPs because the stethoscope remains for
them the best screening tool for VHD.
Assessment of MR severity was
good for primary MR but not for
secondary MR
More than 75% of cardiologists appropriately interpreted the mech-
anism and severity of primary MR cases and concluded that the MR
was due to mitral valve prolapse and was severe. On the other hand,
only 44% recognized that the case with secondary MR was severe.
Are the cardiologists the only ones to blame for their relatively poor
performance in interpreting the echocardiographic severity param-
eters in secondary MR? Certainly not, and the inconsistencies and dis-
cordances in the literature and between the different guidelines may
also have contributed to this situation.
In the 2012 and 2017 ESC-EACTS guidelines,1,2 severe MR is
defined as an effective regurgitant orifice area (EROA) >40 mm2 and
a regurgitant volume (RV) >60 mL in the case of primary MR, but
>20 mm2 and 30 mL, respectively, in the case of secondary MR. First,
having different sets of MR severity cut-off points depending on the
MR aetiology may be misleading for the cardiologists and could cer-
tainly have contributed to the underestimation of the MR severity in
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the case of secondary MR.3 The major difference in the MR severity
cut-off points proposed in the ESC guidelines1,2 between primary
and secondary MR is based on the rationale that patients with sec-
ondary MR generally have depressed left ventricular (LV) function
and are thus more vulnerable to the effect of concomitant MR.
Although this rationale is quite logical, the adjustment of the severity
cut-off points for secondary MR (i.e. two-fold lower than those for
primary MR) is based on very limited published evidence.4 On the
other hand, the 2014 and 2017 ACC-AHA guidelines5,6 have used
the same severity cut-off points (EROA >40 mm2 and RV >60 mL) in
primary and secondary MR, and they also included a regurgitant frac-
tion (RF) >50% as an additional cut-off point for severe MR.
For the sake of clarity and simplification, it is probably preferable
to use the same set of EROA (>40 mm2) and RV (>60 mL) cut-off
points to define haemodynamically severe MR in secondary vs. pri-
mary MR. This approach has the advantage of being applicable in all
types of MR, regardless of the aetiology, i.e. primary, secondary, or
mixed (as is often the case in the elderly population), and of being
more straightforward to apply for the cardiologist. However, it is also
important to distinguish the haemodynamic severity vs. the functional
severity vs. the clinical severity of MR (Take home figure). Although
these three categories of severity are generally (but not always) well
aligned in the context of primary MR, they often diverge in secondary
MR. Hence, a secondary MR (e.g. EROA, 25 mm2; RV, 35 mL) may be
‘volumetrically’ moderate (when using the same cut-off points as pri-
mary MR) but nonetheless ‘haemodynamically’ severe on the basis of
the RF (>50%) if the patient has a low LV ejection fraction (EF) and
low LV output (Take home figure). Hence, when assessing the severity
Take home ﬁgure Proposed strategies for the optimization of management of mitral regurgitation (MR). EROA, effective regurgitant orifice
area; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, NewYork Heart Association Class; RF, regurgitant fraction; RV, regurgi-
tant volume; SPAP, systolic pulmonary arterial pressure.
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of MR in patients with depressed LVEF and secondary MR, more em-
phasis should be put on the RF rather than on EROA and RV. If the
RF is >50%, the MR should be considered severe and managed as
such, even if the EROA and RV are moderate or even mild.
Furthermore, the fact that a secondary MR is volumetrically and
haemodynamically moderate does not necessarily imply that it has no
impact on clinical outcomes (Take home figure). A moderate MR by all
quantitative parameters (e.g. EROA, 25 mm2; RV, 35 mL; RF, 45%)
may actually be very well tolerated by a left ventricle with preserved
LVEF but poorly tolerated by a depressed left ventricle. Hence, a
volumetrically moderate MR may be clinically severe and potentially
require intervention.
The randomized trials of the Cardiothoracic Surgical Network are
certainly the studies that provided the most robust evidence for the
management of secondary ischaemic MR.7,8 In these trials, severe MR
was defined as an EROA >40 mm2 and moderate MR as an EROA
between 20 and 40 mm2, which is in line with the severity criteria
used in primary MR but larger than those proposed by the ESC guide-
lines for secondary MR. In the trial of patients with severe MR,7 mitral
valve replacement provided a more durable correction of MR com-
pared with mitral valve repair, but there was no difference in LV re-
modelling or clinical outcomes between groups. In the trial of
moderate MR,8 the addition of mitral valve repair to coronary artery
bypass grafting provided a more durable correction of MR, but did
not lead to significant differences in terms of LV remodelling or sur-
vival at 1 year. These studies were published in 2014, so after the
2012 ESC-EACTS guidelines and their methods (MR severity cut-off
points), and the results could have influenced the cardiologists’ as-
sessment and interpretation of MR severity. These findings further
emphasize the importance of having the capability to update the
guidelines rapidly when important new studies are published.
Mitral regurgitation, and especially secondary MR, is not static but
highly dynamic (Take home figure). Indeed the severity of MR may in-
crease drastically during exercise and this may negatively impact on
outcomes. This phenomenon may explain why a moderate second-
ary MR (that becomes severe on exercise) may be associated with
poor prognosis and require intervention. In addition, a large propor-
tion of patients with MR (primary or secondary) and normal pulmon-
ary arterial pressures at rest actually develop hypertension during
exercise, and these patients with exercise-induced pulmonary
hypertension exhibit worse outcomes.9,10 The only way to assess the
dynamic component of MR is to perform exercise stress echocardi-
ography. The role of this diagnostic modality should certainly be ex-
panded in the guidelines and in clinical practice (Take home figure).11
Surprisingly, and despite substantial evidence, the role and utility of
exercise stress echocardiography have been downplayed in the 2017
edition of the ESC-EACTS guidelines.2
Medical therapy is overused in
primary MR but underused in
secondary MR
In asymptomatic severe primary MR with an indication for surgery,
the authors reported that ‘27% of PCPs did not refer the patient to a
cardiologist and medical therapy was over-used by 19% of
cardiologists’.3 The term ‘over-used’ is probably too strong because,
in such a situation, the recommendation for mitral valve surgery is a
class IIa with a level of evidence C.1,2 Hence, although it is reasonable
to consider mitral valve surgery in this case, conservative manage-
ment with close follow-up also remains an acceptable option. What
is more concerning in these findings about this primary MR case is
that about one-third of PCPs did not refer this patient with severe
MR to a cardiologist.3 The main reason for this choice of the PCPs
was probably the fact that the patient was asymptomatic. This further
emphasizes the important need for education of PCPs. Obviously,
PCPs do not, and reasonably cannot, know in detail the content of all
guidelines on all diseases including VHDs.
In severe symptomatic secondary MR, optimization of medical
therapy was recommended by only 51% of PCPs and 33% of cardi-
ologists, and surgery was considered in 30% of cases (transcatheter
edge-to-edge repair in 64%). The case scenario proposed in this sur-
vey was complex, and the guidelines for this disease entity are also
complex and differ depending on the medical societies. As mentioned
above, the important discrepancies in the MR severity cut-off points
for secondary MR in the different guidelines and randomized tri-
als1,2,5–8 may have created some uncertainty and confusion with re-
gard to the quantitation and management of secondary MR by the
cardiologists. Furthermore, and in contrast to ACC-AHA guide-
lines,5,6 the ESC-EACTS guidelines1,2 also included other criteria such
as LVEF (< or >30%) and presence/absence of myocardial viability to
decide between medical therapy and surgical management. Given the
limited evidence on the management of secondary MR, a simplifica-
tion of the criteria and algorithms presented in the ESC-EACTS
guidelines could be considered.
MitraClip is frequently proposed
in high-risk patients with primary
MR or secondary MR
This finding is not necessarily surprising because MitraClip allows
elimination or reduction of MR in a less invasive manner compared
with surgery, which is a significant advantage in patients with high sur-
gical risk. Furthermore, several studies on MitraClip experience were
published after the 2012 ESC-EACTS guidelines. These studies may
have encouraged the cardiologists and cardiac surgeons to consider
this procedure more often as an alternative to surgery, although there
was no specific recommendation in the guidelines. Nonetheless, the
MitraClip procedure is not a panacea and may not be able to achieve
complete and durable correction of MR in all patients. Specific and
precise recommendations should be included in the guidelines regard-
ing the utility and limits of this procedure, and these recommenda-
tions should be rapidly updated when new studies are published.
Referral to specialized centres is
mentioned by most cardiologists
This is one of the most important pieces of good news from this sur-
vey.3 The patients with scenarios like those presented in this study
should ideally be referred and followed by specialized heart valve
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..clinics, and, when intervention is contemplated, the patients should
be referred to a heart valve center of excellence or a comprehensive
heart valve centre. The Heart Valve Clinics (Take home figure).12,13
These structures would probably improve the adherence of cardiolo-
gists to the current guidelines. On the other hand, they will not ne-
cessarily solve the issue of underdetection and under-referral of
patients with MR to these specialized structures.
Conclusion
According to the survey of Iung et al., the knowledge and application
of the ESC guidelines for the management of MR are overall adequate
for primary MR but often inappropriate for secondary MR. There is
obviously an important need to develop educational programmes
not only for cardiologists but also, and importantly, for PCPs in order
to better disseminate and apply the recommendations contained in
the guidelines. With regards to the ESC guidelines per se, there is also
a need to: (i) minimize and reconcile the discrepancies with the guide-
lines of other medical societies such as, for example, those of the
ACC-AHA; (ii) simplify, as much as possible, the algorithms and crite-
ria for the management of MR, and especially secondary MR; (iii) give
more emphasis to the role of heart valve clinics and heart valve
centres of excellence; and (iv) develop a mechanism to update rap-
idly, at least in part, the guidelines when important new information is
published.
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